Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 18INDUSTRY 9NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × iberdomide × Clear all
NCT04564703 2025-02-25

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

European Myeloma Network B.V.

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡